Cargando…

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on the risk of developing subsequent disease after an excisional procedure for cervical intraepithelial neoplasia or diagnosis of genital warts, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joura, Elmar A, Garland, Suzanne M, Paavonen, Jorma, Ferris, Daron G, Perez, Gonzalo, Ault, Kevin A, Huh, Warner K, Sings, Heather L, James, Margaret K., Haupt, Richard M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314184/ https://www.ncbi.nlm.nih.gov/pubmed/22454089 http://dx.doi.org/10.1136/bmj.e1401

Ejemplares similares

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region()
por: Castellsagué, Xavier, et al.
Publicado: (2016)

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia
por: Lehtinen, Matti, et al.
Publicado: (2011)

HPV prevalence in vulvar cancer in Austria
por: Pils, Sophie, et al.
Publicado: (2017)

Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease
por: Ghelardi, Alessandro, et al.
Publicado: (2021)

Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
por: Ferris, Daron G., et al.
Publicado: (2020)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
por: Castellsagué, X, et al.
Publicado: (2011)

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
por: Brown, Darron R., et al.
Publicado: (2022)

Localized Provoked Vulvodynia-An Ignored Vulvar Pain Syndrome
por: Paavonen, Jorma, et al.
Publicado: (2021)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee
por: Taumberger, Nadja, et al.
Publicado: (2022)

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
por: Batmunkh, Tsetsegsaihan, et al.
Publicado: (2020)

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination
por: Östensson, Ellinor, et al.
Publicado: (2015)

Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance
por: Gomes, Jéssica Menezes, et al.
Publicado: (2020)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Detection of Human Papillomavirus DNA by AffiProbe HPV-DNA Test Kit in Cervical Scrapes or Biopsies-Histopathologic Correlates
por: Nieminen, Pekka, et al.
Publicado: (1994)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
por: Cespedes, Michelle S., et al.
Publicado: (2018)

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial
por: Pinto, Ligia A., et al.
Publicado: (2016)

Sound efficacy of prophylactic HPV vaccination: Basics and implications
por: Lehtinen, Matti, et al.
Publicado: (2012)

Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2015)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

An investigation into human papillomavirus (HPV) vaccination for patients undergoing surgery for high-grade cervical or vulvar dysplasia
por: Boyles, Glenn P., et al.
Publicado: (2022)

Ongoing inadequacy of quadrivalent HPV vaccine safety studies
por: Little, Deirdre T, et al.
Publicado: (2020)

Human papillomavirus in vulvar and vaginal carcinoma cell lines.
por: Hietanen, S., et al.
Publicado: (1995)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012)

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
por: Villa, L L, et al.
Publicado: (2006)

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
Publicado: (2010)

Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2017)

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
por: Garland, Suzanne M., et al.
Publicado: (2016)

HPV-associated vulvar carcinoma with sebaceous differentiation
por: Kuan, Irena, et al.
Publicado: (2023)

The impact of p16(ink4a) positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study
por: Gensthaler, Lisa, et al.
Publicado: (2020)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery
por: Bekos, Christine, et al.
Publicado: (2019)

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2016)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ga258bvkad7v535mgfdsdnkrk